RxDoctor Payments Data

Logan Lewis

Nurse Practitioner · Pinehurst, NCNPI 1548763428

Payments from drug & device makers

$2,020in general payments, 2019–2025

Across 82 payments — averaging $24.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$266
  • AstraZeneca$212
  • Actelion Pharmaceuticals US, Inc.$169
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$147
  • Boehringer Ingelheim$140
  • Philips North America LLC$114
  • plus $972 from 19 others

What the payments were for

  • Food & beverage$2,020100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,020 in reported general payments places this provider in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$64,188
Medicare patients
728
Services billed
2,430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban82$91,021
JardianceEmpagliflozin59$52,772
EntrestoSacubitril/Valsartan22$22,780
XareltoRivaroxaban18$17,655
MultaqDronedarone Hcl12$9,798
Repatha SureclickEvolocumab12$7,102
Metoprolol Succinate81$854
Ezetimibe26$833
Nebivolol Hcl14$769
Amlodipine Besylate90$498
Telmisartan16$467
Valsartan21$440
Torsemide37$410
Atorvastatin Calcium35$346
Spironolactone27$326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$110$91,02182 claims
Boehringer IngelheimJardiance$140$52,77259 claims
NovartisEntresto$44$22,78022 claims
Johnson & JohnsonXarelto$113$17,65518 claims
Sanofi-aventis U.S. LLCMultaq$69$9,79812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Pinehurst

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →